European Patent office relaxes law on second use claims
This article was originally published in Scrip
The Enlarged Board of Appeals (EBA) of the European Patent Office has issued an important decision that is expected to relax the law on second medical use claims. The ruling, legal experts believe, may be of considerable significance for the pharmaceutical industry, where new patents are often sought to protect novel and inventive uses of known medicines.
You may also be interested in...
Drug companies will be able to “play around” with the new EU Clinical Trials Information System in a secure testing environment before it goes live in approximately 15 months.
The Canadian authorities have put in place an expedited pathway for authorizing new COVID-19 drugs and vaccines that offers a more agile approach to reviewing data than what was previously allowed.
A new pre-assessment service for COVID-19 clinical trials that was established by the UK medicines regulator to cut down on review times is being extended to a limited number of other kinds of trials.